Maraviroc, originally designated UK-427857, is a small molecule and the first oral antiretroviral drug in the CCR5 receptor antagonist class used in the treatment of HIV infection. This drug classed as an entry inhibitor, was developed by the drug company Pfizer in its UK labs located in Sandwich. On April 24, 2007 the U.S. Food and Drug Administration advisory panel reviewing maraviroc's New Drug Application unanimously recommended approval for the new drug, and the drug received full FDA approval on August 6, 2007 for use in treatment experienced patients. Maraviroc is extensively metabolized by CYP3A4, with renal clearance accounting for approximately 23% of total clearance and has been shown to achieve an undetectable HIV-1 RNA level in clinically advanced, class three antiretroviral treatmentexperienced adults with evidence of CCR5-tropic HIV-1 replication despite ongoing antiretroviral therapy. It is well tolerated, and its development is responding to a desperate need for new classes of antiretroviral agents that can target novel steps of the HIV lifecycle and do not share cross resistance with currently available therapy. This CCR5 receptor antagonist reviews clinically relevant pharmacological, long term therapeutic efficacy.Our case report aims to explain the impact of Maraviroc co-administered with agents from all classes of antiretroviral therapy in a HIV-1 experienced patient along eleven years of antiretroviral experience.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.